Actually it's a pretty good example. In Australia, medicines and medical devices (i.e. 81% of J&J revenue) are regulated by the same body (the TGA) using the same approach, craftily reasoning that sick people need both. I realise you might see thing differently (i.e. better) in the USA, but I guess that's just part of what makes you exceptional!

Medical devices and pharmaceutical companies have different cost structures, so I maintain my point that J&J is not a good example of a pharmaceutical cost structure.

But you did 10 minutes of Googling so I defer to you I guess.

"Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses."

  -- https://en.wikipedia.org/wiki/Johnson_%26_Johnson

Literally every single one of those products listed fall under their 'Consumer Segment' (see pages 7 & 8 of financial statements in original post). The entire consumer segment accounts for 18.5 per cent of their total revenue.

The remaining 81.5 per cent of their revenue comes from the sale of pharmaceuticals and medical devices.

The original post was listing the "consolidated" figures. Marketing of consumer products was not broken out separately from the consolidated figures.

The information in the pdf does not support the narrative of the original article, because of the use of consolidated figures.